Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 11/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.60 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203379 | 0.89 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DACHE | |
| SCHEMBL3534915 | 0.87 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DACHE | |
| SCHEMBL5202079 | 0.77 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DACHE | |
| SCHEMBL5201775 | 0.75 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DACHE | |
| SCHEMBL3533473 | 0.74 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DACHE | |
| SCHEMBL13009783 | 0.74 | ACHE (0.66) | ACHESLC2A1TLR9TLR7GBA1 | |
| SCHEMBL5201778 | 0.71 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9756638 | 0.69 | GBA1 (0.49) | ACHETLR9TLR7KITGBA1 | |
| SCHEMBL3637851 | 0.69 | SLC2A1 (0.54) | ACHESLC2A1TLR9TLR7 | |
| SCHEMBL3539405 | 0.68 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718654-B2 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-18 | — | — | US | disclosed |
| US-20060116371-A1 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116371-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | PDE4A 1428/4885PDE4B 1709/4885PDE4C 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.